X @Bloomberg

Financial Performance - Biogen cut its full-year profit guidance [1] Business Strategy - The company is doing deals to offset the decline of its aging multiple sclerosis drugs [1] Cost Analysis - Higher costs are associated with the deals Biogen has been doing [1]